Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.09
-0.12 (-1.66%)
Nov 4, 2024, 4:00 PM EST - Market closed
Kezar Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 7 | 7 | - | - | - | - | |
| Cost of Revenue | 79.85 | 85.7 | 51.01 | 38.94 | - | - | |
| Gross Profit | -72.85 | -78.7 | -51.01 | -38.94 | - | - | |
| Selling, General & Admin | 26.69 | 26.54 | 20.15 | 15.72 | 11.97 | 9.98 | |
| Research & Development | - | - | - | - | 30.98 | 27.36 | |
| Operating Expenses | 26.69 | 26.54 | 20.15 | 15.72 | 42.95 | 37.34 | |
| Operating Income | -99.54 | -105.24 | -71.16 | -54.66 | -42.95 | -37.34 | |
| Interest Expense | -1.6 | -1.55 | -1.19 | -0.16 | - | - | |
| Interest & Investment Income | 10.24 | 11.1 | 4.11 | 0.19 | 1.21 | 2.26 | |
| EBT Excluding Unusual Items | -90.9 | -95.68 | -68.24 | -54.63 | -41.74 | -35.09 | |
| Merger & Restructuring Charges | -7.67 | -6.19 | - | - | - | - | |
| Pretax Income | -98.57 | -101.87 | -68.24 | -54.63 | -41.74 | -35.09 | |
| Net Income | -98.57 | -101.87 | -68.24 | -54.63 | -41.74 | -35.09 | |
| Net Income to Common | -98.57 | -101.87 | -68.24 | -54.63 | -41.74 | -35.09 | |
| Shares Outstanding (Basic) | 7 | 7 | 7 | 5 | 4 | 2 | |
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 5 | 4 | 2 | |
| Shares Change (YoY) | 0.60% | 7.70% | 27.69% | 19.90% | 130.58% | 85.92% | |
| EPS (Basic) | -13.55 | -14.04 | -10.13 | -10.35 | -9.49 | -18.39 | |
| EPS (Diluted) | -13.55 | -14.04 | -10.13 | -10.35 | -9.49 | -18.39 | |
| Free Cash Flow | -79.22 | -83.46 | -60.42 | -42.75 | -37.14 | -30.48 | |
| Free Cash Flow Per Share | -10.89 | -11.50 | -8.97 | -8.10 | -8.44 | -15.97 | |
| Operating Margin | -1422.01% | -1503.39% | - | - | - | - | |
| Profit Margin | -1408.11% | -1455.29% | - | - | - | - | |
| Free Cash Flow Margin | -1131.64% | -1192.21% | - | - | - | - | |
| EBITDA | -98.46 | -104.17 | -70.14 | -53.15 | -41.41 | -36.04 | |
| D&A For EBITDA | 1.08 | 1.07 | 1.02 | 1.51 | 1.54 | 1.3 | |
| EBIT | -99.54 | -105.24 | -71.16 | -54.66 | -42.95 | -37.34 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.